Atossa Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company raised $4.5 million in upfront gross proceeds from a registered direct offering of common stock and warrants, with potential additional proceeds up to $12 million upon full warrant exercise. Total operating expenses were $8.7 million for the three months ended June 30, 2026, compared to $9.0 million in the prior year period. The company also announced that enrollment in its Phase 2 EVANGELINE trial was completed and highlighted new preclinical data regarding (Z)-endoxifen's potential in rare pediatric diseases and breast cancer. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need.

Atossa Therapeutics, Inc. entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants. The combined offering price is $3.30 per share, with the company expecting net proceeds of approximately $4.1 million after expenses. The warrants have an exercise price of $4.40 per share and could provide an additional $12 million in gross proceeds if fully exercised. Rodman & Renshaw LLC is serving as the exclusive placement agent. Net proceeds are intended for clinical development, working capital, and general corporate purposes. Atossa Therapeutics is a biopharmaceutical company focused on developing therapeutic products.